ECSP20023043A - Amidas de imidazopiridina sustituidas y su uso - Google Patents

Amidas de imidazopiridina sustituidas y su uso

Info

Publication number
ECSP20023043A
ECSP20023043A ECSENADI202023043A ECDI202023043A ECSP20023043A EC SP20023043 A ECSP20023043 A EC SP20023043A EC SENADI202023043 A ECSENADI202023043 A EC SENADI202023043A EC DI202023043 A ECDI202023043 A EC DI202023043A EC SP20023043 A ECSP20023043 A EC SP20023043A
Authority
EC
Ecuador
Prior art keywords
diseases
prophylaxis
treatment
substituted imidazopyridine
amides
Prior art date
Application number
ECSENADI202023043A
Other languages
English (en)
Inventor
Walter Kroh
Kersten Matthias Gericke
Jan Stampfuss
Daniel Meibom
Klaus Münter
Nina Alexandra Scheerer
Jutta Meyer
Till Freudenberger
Thomas Mondritzki
Frank Wunder
Karl Collins
Mario Lobell
Alexander Straub
Hernandez Nuria Ortega
Jens Schamberger
Kirsten Leineweber
Original Assignee
Bayer Ag
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60162133&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP20023043(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Ag, Bayer Pharma AG filed Critical Bayer Ag
Publication of ECSP20023043A publication Critical patent/ECSP20023043A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente solicitud se refiere a nuevas amidas de imidazopiridinas sustituidas de la fórmula (I), a procedimientos para su preparación, al uso de los mismos por sí solos o en combinación para el tratamiento y / o la profilaxis de enfermedades y al uso para la preparación de medicamentos para el tratamiento y / o la profilaxis de enfermedades, en particular para el tratamiento y / o la profilaxis de enfermedades cardiovasculares, neurológicas y del sistema nervioso central, así como enfermedades metabólicas.
ECSENADI202023043A 2017-10-24 2020-04-21 Amidas de imidazopiridina sustituidas y su uso ECSP20023043A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP17198021 2017-10-24

Publications (1)

Publication Number Publication Date
ECSP20023043A true ECSP20023043A (es) 2020-06-30

Family

ID=60162133

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202023043A ECSP20023043A (es) 2017-10-24 2020-04-21 Amidas de imidazopiridina sustituidas y su uso

Country Status (27)

Country Link
US (1) US20200339567A1 (es)
EP (1) EP3700903A1 (es)
JP (1) JP2021500366A (es)
KR (1) KR20200076686A (es)
CN (1) CN111225917A (es)
AR (1) AR113790A1 (es)
AU (1) AU2018354785A1 (es)
BR (1) BR112020007967A2 (es)
CA (1) CA3084422A1 (es)
CL (1) CL2020001075A1 (es)
CO (1) CO2020004968A2 (es)
CR (1) CR20200173A (es)
CU (1) CU20200041A7 (es)
DO (1) DOP2020000072A (es)
EA (1) EA202091020A1 (es)
EC (1) ECSP20023043A (es)
IL (1) IL273954A (es)
JO (1) JOP20200073A1 (es)
MA (1) MA50440A (es)
MX (1) MX2020004190A (es)
NI (1) NI202000029A (es)
PE (1) PE20201280A1 (es)
PH (1) PH12020550472A1 (es)
SG (1) SG11202003641RA (es)
TW (1) TW201932462A (es)
UY (1) UY37947A (es)
WO (1) WO2019081353A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI877770B (zh) 2018-02-27 2025-03-21 美商英塞特公司 作為a2a / a2b抑制劑之咪唑并嘧啶及三唑并嘧啶
EP3810610A1 (en) 2018-05-18 2021-04-28 Incyte Corporation Fused pyrimidine derivatives as a2a / a2b inhibitors
WO2020010197A1 (en) 2018-07-05 2020-01-09 Incyte Corporation Fused pyrazine derivatives as a2a / a2b inhibitors
CA3124088A1 (en) 2018-12-20 2020-06-25 Incyte Corporation Imidazopyridazine and imidazopyridine compounds as inhibitors of activin receptor-like kinase-2
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
WO2020216669A1 (de) * 2019-04-23 2020-10-29 Bayer Aktiengesellschaft Phenylsubstituierte imidazopyridinamide und ihre verwendung
CN116234549B (zh) 2020-08-05 2025-11-25 总医院公司 盐诱导激酶抑制剂
WO2023086390A1 (en) * 2021-11-09 2023-05-19 Tufts Medical Center, Inc. Methods and compositions for providing myocardial protection and treating myocardial stress and fibrosis
CN117510444B (zh) * 2024-01-06 2024-03-08 成都瑞尔医药科技有限公司 一种呋塞米的精制工艺

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DE19943639A1 (de) 1999-09-13 2001-03-15 Bayer Ag Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
CN1173975C (zh) 2000-04-27 2004-11-03 山之内制药株式会社 咪唑并吡啶衍生物
AR031176A1 (es) 2000-11-22 2003-09-10 Bayer Ag Nuevos derivados de pirazolpiridina sustituidos con piridina
WO2003008387A1 (en) 2001-07-20 2003-01-30 Oy Juvantia Pharma Ltd Compounds useful for treatment or prevention of disease mediated by alpha-2b-adrenoceptor
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
WO2008027812A2 (en) 2006-08-28 2008-03-06 Forest Laboratories Holdings Limited Imidazopyridine and imidazopyrimidine derivatives
WO2008134553A1 (en) 2007-04-26 2008-11-06 Xenon Pharmaceuticals Inc. Methods of using bicyclic compounds in treating sodium channel-mediated diseases
GB0720041D0 (en) * 2007-10-12 2007-11-21 Astex Therapeutics Ltd New Compounds
GB0720038D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New compounds
EP2334676B1 (en) 2008-09-17 2016-07-06 Allergan, Inc. Substituted 3-amino-1-oxo or thioxo-1,2,5,6,7,8-hexahydro-2,7-naphthyridine-4-carbonitriles as selective alpha 2b antagonists
DE102010001064A1 (de) 2009-03-18 2010-09-23 Bayer Schering Pharma Aktiengesellschaft Substituierte 2-Acetamido-5-Aryl-1,2,4-triazolone und deren Verwendung
UA109650C2 (xx) 2010-02-27 2015-09-25 Біс-арилзв'язані арилтриазолони та їх застосування
DE102010021637A1 (de) 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
TW201242965A (en) * 2011-02-01 2012-11-01 Kyowa Hakko Kirin Co Ltd Ring-fused heterocyclic derivative
US8791162B2 (en) 2011-02-14 2014-07-29 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
DE102011007272A1 (de) 2011-04-13 2012-10-18 Bayer Pharma Aktiengesellschaft Verzweigte 3-Phenylpropionsäure-Derivate und ihre Verwendung
CN104619709B (zh) 2012-07-13 2016-11-09 Ucb生物制药私人有限公司 作为tnf活性调节剂的咪唑并吡啶衍生物
RS55651B1 (sr) 2012-07-20 2017-06-30 Bayer Pharma AG Nove 5-aminotetrahidrohinolin-2-karbonske kiseline i njihova upotreba
US9624214B2 (en) 2012-11-05 2017-04-18 Bayer Pharma Aktiengesellschaft Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use
MX2015010966A (es) 2013-03-01 2016-04-04 Bayer Pharma AG Pirimidinas fusionadas sustituidas con trifluorometilo y sus usos.
SI3215498T1 (sl) 2014-11-03 2018-11-30 Bayer Pharma Aktiengesellschaft Hidroksialkil-substituirani derivati feniltriazola in njihove uporabe

Also Published As

Publication number Publication date
US20200339567A1 (en) 2020-10-29
CN111225917A (zh) 2020-06-02
AU2018354785A1 (en) 2020-04-23
CR20200173A (es) 2020-06-26
KR20200076686A (ko) 2020-06-29
EA202091020A1 (ru) 2020-07-24
AR113790A1 (es) 2020-06-10
DOP2020000072A (es) 2020-08-31
MA50440A (fr) 2020-09-02
CO2020004968A2 (es) 2020-05-05
PE20201280A1 (es) 2020-11-24
TW201932462A (zh) 2019-08-16
JP2021500366A (ja) 2021-01-07
SG11202003641RA (en) 2020-05-28
UY37947A (es) 2019-05-31
BR112020007967A2 (pt) 2020-10-20
WO2019081353A1 (de) 2019-05-02
PH12020550472A1 (en) 2021-03-15
NI202000029A (es) 2020-10-09
MX2020004190A (es) 2020-08-03
JOP20200073A1 (ar) 2020-04-29
CU20200041A7 (es) 2021-03-11
IL273954A (en) 2020-05-31
CL2020001075A1 (es) 2021-01-22
EP3700903A1 (de) 2020-09-02
CA3084422A1 (en) 2019-05-02

Similar Documents

Publication Publication Date Title
NI202000029A (es) Amidas de imidazopiridina sustituidas y su uso
UY37124A (es) Nuevos compuestos de 6,7-dihidro-5h-benzo[7]anuleno sustituidos, procesos para su preparación y usos terapéuticos de los mismos
CU20190101A7 (es) Imidazopirimidinas diazabicíclicas sustituidas
CO2017011851A2 (es) Compuestos novedosos
CL2018001624A1 (es) Antagonistas policíclicos del tlr7/8 y uso de los mismos en el tratamiento de trastornos inmunitarios
MX382331B (es) Derivados de 6,7,8,9-tetrahidro-3h-pirazolo[4,3f] isoquinolina útiles en el tratamiento del cáncer.
DOP2018000204A (es) Moduladores alostéricos de receptores de acetilcolina nicotínicos
DOP2016000281A (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer
MX2016015248A (es) Compuestos imidazo[1,2-a]pirazin-1-il-benzamida para tratar atrofia muscular espinal.
GT201400222A (es) Agentes para tratar trastornos que implican la modulación de receptores de rianodina
MX2016014308A (es) Compuestos y composiciones como agonistas del receptor tipo toll 7.
ECSP15006871A (es) 4-metil-2,3,5,9,9b-pentaaza-ciclopenta[a]naftalenos
CR20160558A (es) Compuesto de 1, 3, 4 - tiadiazol y uso de los mismos para el tratamiento del cáncer
CL2016002091A1 (es) Compuesto de triazina y su uso para fines medicinales
MX370900B (es) Derivados del isocromeno como inhibidores de las fosfoinositido-3 cinasas.
UY35344A (es) Oestra-1,3,5(10),16-tetraeno-3-carboxamidas
ECSP14002542A (es) Nuevos 2h–indazoles como antagonistas del receptor ep2
DOP2016000170A (es) Compuestos derivados de hidroxiformamida y usos del mismo
CO2019011227A2 (es) N-ariletil-2-aminoquinolin-4-carboxamidas sustituidas y su uso
CR20160155A (es) Tienouracilcarboxamidas cíclicas y usos de las mismas
DOP2017000018A (es) [1,2,4]triazolo[4,3-b]piridazinas para su uso en el tratamiento de enfermedades proliferativas
CO2020001506A2 (es) Nuevos compuestos
MX2017009608A (es) Compuestos anticancerigenos.
MX2019011265A (es) Derivados del acido acetico azaindol y su uso como moduladores de receptor de prostaglandina d2.
CL2016001024A1 (es) Compuestos derivados de pirido[4,3-b]pirazin-2-carboxamidas; procedimiento de preparacion; composicion farmaceutica y uso para el tratamiento de trastornos neurodegenerativos, esquizofrenia, depresion, entre otras enfermedades.